New concepts in antimicrobial resistance in cystic fibrosis respiratory infections

J Cyst Fibros. 2022 Nov;21(6):937-945. doi: 10.1016/j.jcf.2022.10.005. Epub 2022 Oct 18.

Abstract

In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17th European Cystic Fibrosis Society Basic Science Conference, held from 30 March to 2 April, 2022 in Albufeira, Portugal. Keynote lectures provided an update on the latest information regarding the phenomenon of antimicrobial resistance (AMR) in cystic fibrosis (CF). Traditional themes such as in vitro antibiotic susceptibility testing and its clinical value, AMR evolution in persistent Pseudomonas aeruginosa infection and the impact of biofilm on AMR were discussed. In addition, the report gives an overview on very recent AMR-related topics that include an ecological view of AMR in CF lung, referred to as resistome, and novel anti-infective approaches in preclinical or early clinical research such as antibiofilm drugs and bacteriophages.

Keywords: Antimicrobial resistance; Antimicrobial strategies; Antimicrobial susceptibility testing; Biofilm; Pathoadaptation; Resistome.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Drug Resistance, Bacterial
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections* / diagnosis
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa
  • Respiratory Tract Infections* / drug therapy

Substances

  • Anti-Bacterial Agents